Evaluation of therapeutic effect of tumor-targeted therapy.

about

Evaluation of therapeutic effect of tumor-targeted therapy.

Item

http://www.wikidata.org/entity/Q41962463

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Evaluation of therapeutic effect of tumor-targeted therapy.

@en

type

Item

label

Evaluation of therapeutic effect of tumor-targeted therapy.

@en

prefLabel

Evaluation of therapeutic effect of tumor-targeted therapy.

@en

P1476

Evaluation of therapeutic effect of tumor-targeted therapy.

@en

P2093

Hong Shen

http://www.w3.org/2001/XMLSchema#string

Mo-Dan Li

http://www.w3.org/2001/XMLSchema#string

Pin-Tong Huang

http://www.w3.org/2001/XMLSchema#string

Xiao-Fen Li

http://www.w3.org/2001/XMLSchema#string

Xue-Feng Fang

http://www.w3.org/2001/XMLSchema#string

Ying Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results 1

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Reporting results of cancer treatment

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications.

Rituximab: ongoing and future clinical development.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

P304

191-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S36307

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232226370

http://www.w3.org/2001/XMLSchema#string

P698

23049263

http://www.w3.org/2001/XMLSchema#string

P932

3459839

http://www.w3.org/2001/XMLSchema#string